Skip to contentpdufa.bio

JIDEYTRO (zidesamtinib): FDA NDA 220185

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 220185 is the FDA application for JIDEYTRO (zidesamtinib). The FDA's Orange Book lists the applicant of record as NUVALENT INC and the first approval on it as Jul 22, 2026. Code name used in development: NVL-520. Owner today: GSK plc (LSE/NYSE: GSK).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 220185 · Orange Book NDA 220185

Names for this drug

Brand name (FDA)JIDEYTRO
Orange Book trade name: JIDEYTRO
Active ingredient (FDA)ZIDESAMTINIB
Code nameNVL-520
Source: GSK press release, Jun 9, 2026
“Zidesamtinib (NVL-520) and neladalkib (NVL-655) are two late-stage, potential best-in-class,”

Who holds the application

FDA applicant of recordNUVALENT INC
FDA Orange Book data files as of Nov 13, 2026
Owner todayGSK plc (GSK)
Source: GSK press release, Jul 22, 2026
“GSK plc (LSE/NYSE: GSK)” … “part of the portfolio from the recently completed acquisition of Nuvalent, Inc.”
Earlier / partnerNuvalent, Inc. (ticker at the time: NUVL): acquired by the current owner, Jul 15, 2026
Source: GSK 6-K, Jul 15, 2026
“GSK plc (LSE/NYSE: GSK) today announced completion of its acquisition of Nuvalent, Inc.” … “Nuvalent (NASDAQ: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted”

Products on NDA 220185 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001JIDEYTROTABLET;ORAL25MGJul 22, 2026
002JIDEYTROTABLET;ORAL100MGJul 22, 2026

FDA decisions we track for this drug

Zidesamtinib (NVL-520) - (ARROS-1)NUVL · Decided

Drug page: /drug/zidesamtinib

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.